TNBC remains one of the most aggressive forms of breast cancer, characterized by the absence of estrogen, progesterone, and HER2 receptors. This receptor-negative profile limits targeted treatment options, leaving chemotherapy as the primary systemic intervention. However, clinical outcomes to chemotherapy in TNBC are notoriously variable, suggesting underlying biological heterogeneity that has remained elusive until now. Recognizing this therapeutic challenge, the researchers sought a deeper comprehension of tumor-intrinsic and microenvironmental determinants driving response variability.

Leveraging fresh pre-treatment tumor biopsies from 101 TNBC patients, the investigators conducted single-cell RNA sequencing encompassing more than 427,000 individual cells. This comprehensive cellular atlas was complimented by spatial transcriptomic mapping of tumors from 44 patients, allowing the integration of gene expression data with cellular localization within the tumor architecture. A rigorous comparative analysis was performed against the Human Breast Cell Atlas, a reference database cataloging the normal breast tissue cellular milieu, enabling precise discrimination of malignant and non-malignant cell populations.

Through this large-scale cellular deconstruction, TNBC tumors were stratified into four archetypal profiles based on cancer cell transcriptional signatures. Crucially, a coherent set of thirteen highly expressed, cancer-specific genes emerged as a transcriptional signature underpinning these archetypes. This gene panel reflects a coordinated regulatory program influencing tumor cell phenotypes and their crosstalk with the surrounding microenvironment. Such molecular stratification advances beyond traditional histopathological classifications, offering a granular lens into tumor heterogeneity.

Integral to their findings was the characterization of macrophage populations within the TNBC tumor microenvironment. Macrophages, versatile immune cells known for roles in phagocytosis and immune regulation, exhibited distinct subtypes with divergent associations to therapy response. The study identified 49 immune cell states consolidated into eight spatially consistent cell neighborhoods, each correlating with specific cancer archetypes and neoadjuvant chemotherapy outcomes. Notably, certain macrophage subsets displayed gene expression programs linked to either pro-tumoral or anti-tumoral functions, suggesting their pivotal role in modulating chemotherapy efficacy.

Prevailing TNBC research has often focused on T cells within the tumor immune milieu; however, this comprehensive study illuminates the critical influence of macrophage heterogeneity. The discovery of macrophage-associated transcriptional signatures coexisting with cancer cell states sheds light on intricate tumor-immune interactions that may drive differential drug sensitivities. These insights underscore macrophages as potential biomarkers and therapeutic targets, offering avenues for immunomodulatory strategies tailored to TNBC’s complex ecosystem.

To translate these biological insights into clinically actionable tools, the researchers developed a machine learning model informed by the 13-gene transcriptional signature. This predictive model demonstrated robust capacity to forecast patient-level responses to chemotherapy prior to treatment initiation, paving the way for precision oncology approaches. By anticipating therapeutic outcomes, clinicians could potentially refine treatment regimens, avoid unnecessary toxicity, and enhance patient survival.

The methodological innovation of integrating single-cell genomics with spatial transcriptomics exemplifies a paradigm shift in cancer biology. This approach captures both gene expression nuances and tissue architecture, enabling a multidimensional understanding of tumor biology—a necessity for deciphering TNBC’s notorious heterogeneity. The scale and depth of this dataset represent one of the largest single-cell genomic efforts conducted in TNBC to date, setting a new benchmark for future studies.

Looking ahead, these findings hold promise for transforming TNBC management by enabling personalized treatment strategies informed by tumor-specific cellular and molecular features. While prospective clinical validation is requisite before routine adoption, the identification of macrophage subtypes and the gene panel offers a biologically rational foundation for new diagnostics and therapeutic innovations, including macrophage-targeted therapies and combination immunochemotherapy.

Dr. Nicholas Navin, chair of Systems Biology at MD Anderson, emphasized the novelty of this work in dissecting gene-expression programs and immune cell architecture in TNBC. Similarly, Dr. Clinton Yam, associate professor of Breast Medical Oncology, highlighted the potential of these discoveries to revolutionize treatment prediction and patient care, marking a significant stride toward individualized breast cancer therapy with improved efficacy and reduced morbidity.

This study was made possible through extensive collaborations and funding support from prominent institutions including the NIH, NCI, CPRIT, and multiple philanthropic foundations. The comprehensive author disclosures and detailed findings are accessible through the Nature publication, underscoring the rigor and transparency underpinning this seminal work.

In conclusion, this expansive investigation unravels the layered complexity of TNBC’s tumor microenvironment and cancer cell heterogeneity, spotlighting macrophage diversity and a targeted gene expression signature as key determinants of chemotherapy response. By integrating cutting-edge single-cell technologies with sophisticated computational models, this research paves the way for precision medicine approaches that could markedly improve therapeutic outcomes and quality of life for patients battling triple-negative breast cancer.

Subject of Research: Triple-negative breast cancer tumor microenvironment characterization and chemotherapy response prediction

Article Title: A 13-gene transcriptional signature and macrophage subtypes predict chemotherapy response in triple-negative breast cancer

News Publication Date: May 13, 2026

Web References:

• The University of Texas MD Anderson Cancer Center: http://www.mdanderson.org
• Nature publication: https://www.nature.com/articles/s41586-026-10469-9
• Human Breast Cell Atlas: https://navinlabcode.github.io/HumanBreastCellAtlas.github.io/

References:
Navin, N., Yam, C., et al. (2026). Single-cell transcriptional profiling identifies macrophage subtypes associated with chemotherapy response in triple-negative breast cancer. Nature. https://doi.org/10.1038/s41586-026-10469-9

Image Credits: The University of Texas MD Anderson Cancer Center

Keywords: Triple-negative breast cancer, chemotherapy response, tumor microenvironment, single-cell analysis, spatial transcriptomics, macrophages, gene expression, transcriptional signature, machine learning, cancer genomics, immuno-oncology, personalized medicine

Colorectal cancer remains a formidable global health challenge, ranking as the second leading cause of cancer-related deaths according to the World Health Organization. Despite advancements in treatment, a significant hurdle remains: the majority of CRC cases are detected at late stages, severely limiting therapeutic options. Contributing to this problem is the reliance on existing screening modalities such as colonoscopies and stool-based kits, which suffer from low patient compliance due to their invasive or unpleasant nature, as well as suboptimal accuracy in identifying early-stage cancers.

The CASPDx CRC test seeks to circumvent these issues by detecting specific inflammatory biomarkers in the bloodstream—molecular signals intricately linked to the tumor microenvironment and the progression of colorectal malignancies. Dr. Emma Creagh, the scientific lead and Associate Professor of Biochemistry at Trinity College Dublin, explains that inflammation plays a dual role, essential for immune surveillance and tissue repair yet paradoxically facilitating cancer development and spread when dysregulated. Their research identifies precise inflammatory markers whose elevated presence in the blood correlates with CRC onset and advancement, enabling this blood test to serve as an early warning system for patients at risk.

This cutting-edge diagnostic approach is currently undergoing formal validation across multiple Bowel Screen Centres in the Health Service Executive’s Dublin and South East region, supported by collaboration with the UCD Clinical Research Centre. These multicentric clinical studies are critical to establishing the test’s sensitivity, specificity, and reproducibility before its anticipated market introduction, aimed for late 2027. Successful commercialization will facilitate widespread access, bridging the gap between scientific innovation and clinical application.

CRC presents a particular concern in younger populations, evidenced by a near doubling in incidence rates among individuals under 50 over the past three decades. Alarmingly, early-onset colorectal cancer often manifests more aggressively and is diagnosed at more advanced stages, partly due to screening protocols that typically commence at or after the age of 50. Consequently, the CASPDx CRC test could also redefine screening paradigms by facilitating earlier detection in younger, otherwise undiagnosed demographics.

Dr. Kieran Clarke, Commercial Lead for CASPDx, underscores the urgent need for better diagnostics by highlighting the vast numbers of unscreened individuals—estimated at nearly 120 million across the US and EU. The envisioned test combines affordability and scalability with high diagnostic accuracy, attributes that are essential for integration into existing healthcare systems and national screening programs. Clarke emphasizes that the support from Enterprise Ireland’s fund enables the recruitment of specialized teams needed to accelerate development, validate the assay clinically, and ultimately transfer the technology from laboratory to patient care.

A pressing challenge in CRC management is the burden placed on healthcare infrastructures by invasive diagnostics such as colonoscopy, which not only cause discomfort to patients but also face long waiting lists. Prof. Glen Doherty, Consultant Gastroenterologist at St Vincent’s University Hospital, stresses that a reliable blood-based screening tool could significantly refine patient triage pathways. By accurately distinguishing true positives following initial stool test screening, the CASPDx CRC test promises to optimize colonoscopy utilization, reduce unnecessary procedures, and allow resources to focus on patients with confirmed malignancies.

The socio-economic impact of colorectal cancer is profound. The disease was estimated to cost the European Union approximately €19 billion in 2020 alone, a figure reflecting direct healthcare expenses, lost productivity, and broader societal impacts. Current diagnostics, particularly novel technologies offering enhanced accuracy, often remain prohibitively expensive and geographically limited, underscoring the value of CASPDx’s approach in democratizing access to quality screening.

Enterprise Ireland’s Research Commercialisation Unit has recognized the potential of CASPDx, endorsing it as a paradigm-shifting technology in the colorectal cancer screening arena. Their funding is instrumental in supporting an interdisciplinary team from academia and clinical practice, fostering innovation that merges cutting-edge biochemistry, immunoassay development, and clinical expertise.

At the heart of this initiative is a multidisciplinary leadership ensemble combining scientific acumen, clinical insight, and commercial expertise. Alongside Dr. Emma Creagh, the team includes Dr. Paul Leonard, Development Lead at Dublin City University, who brings extensive experience in molecular biology and recombinant antibody technology—key to the development of sensitive immunoassays tailored to inflammatory markers. Dr. Kieran Clarke’s background in launching diagnostic products internationally complements this expertise, and Prof. Glen Doherty provides essential clinical guidance rooted in his frontline gastroenterological experience.

This collaboration exemplifies the model of translational research where fundamental biochemical discoveries about inflammation and its connection to cancer are harnessed to create tools with the potential to save lives. The CASPDx CRC test is emblematic of precision diagnostics that move beyond symptom-based detection to molecularly informed screening, enhancing early intervention opportunities.

In summary, the CASPDx CRC test represents a beacon of hope in colorectal cancer diagnostics, promising a more patient-friendly, cost-effective, and accurate screening alternative. By intercepting cancer development through the detection of blood-based inflammatory biomarkers, it aims not only to improve survival rates but also to alleviate healthcare burdens. As clinical trials and validation efforts progress, the global healthcare community watches with anticipation for this transformative innovation poised to reshape the future of bowel cancer screening.

Subject of Research: Development of a blood-based screening test for colorectal cancer using inflammatory biomarkers

Article Title: Breakthrough Blood Test Promises Early Detection of Colorectal Cancer through Inflammatory Biomarkers

News Publication Date: Information not provided

Web References: Information not provided

References: Information not provided

Image Credits: Thomas Deane, Trinity College Dublin

Keywords: colorectal cancer, blood-based screening, inflammatory biomarkers, cancer diagnostics, CASPDx, early detection, colorectal cancer screening, immunoassay development, cancer inflammation, non-invasive diagnostics, cancer biomarker test, clinical validation